Self-medication with analgesics reported by patients with ulcerative colitis: An anonymous survey

Rodríguez-Lago, Iago; Mesonero, Francisco; Hijos-Mallada, Gonzalo; Cañas, Mercedes; Saldaña, Roberto; Savini, Claudia; Fernández, Sabela; Juliá, Berta; Cea-Calvo, Luis.
Gastroenterol. hepatol. (Ed. impr.) ; 45(6): 457-463, Jun-Jul. 2022. graf, tab
Artículo en Inglés | IBECS (España) | ID: ibc-204391

Documentos relacionados

  1. Self-medication with analgesics reported by patients with ulcerative colitis: An anonymous survey.
  2. Tofacitinib real-world experience in ulcerative colitis in Finland (FinTofUC): a retrospective non-interventional multicenter patient chart data study.
  3. A practical guide to selecting and using new ulcerative colitis therapies.
  4. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.
  5. Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center.
  6. In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events.
  7. GADECCU 2022 Guideline for the treatment of Ulcerative Colitis. Adaptation and updating of the GETECCU 2020 Guideline.
  8. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
  9. Outcomes out to 12 months after sequential use of high-dose tofacitinib following infliximab in acute severe ulcerative colitis.
  10. Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.